מדינה: ארצות הברית
שפה: אנגלית
מקור: NLM (National Library of Medicine)
Prednisone (UNII: VB0R961HZT) (Prednisone - UNII:VB0R961HZT)
JUBILANT CADISTA PHARMACEUTICALS INC.
ORAL
PRESCRIPTION DRUG
Prednisone Tablets, USP are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis. 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus
Prednisone Tablets, USP are available in the following strengths and package sizes: 2.5 mg - White, round tablets debossed with "C 782" on one side and scored on the other side. Bottles of 30 tablets with Child Resistant Closure, NDC 59746-782-30 Bottles of 100 tablets with Child Resistant Closure, NDC 59746-782-01 5 mg - White, round tablets debossed with "TL 172" on one side and scored on the other side. Bottles of 100 tablets with Child Resistant Closure, NDC 59746-172-06 Bottles of 1000 NDC 59746-172-10 10 mg - White, round tablets debossed with "TL 173" on one side and scored on the other side. Bottles of 100 tablets with Child Resistant Closure, NDC 59746-173-06 Bottles of 500 NDC 59746-173-09 Bottles of 1000 NDC 59746-173-10 20 mg - Peach, round tablets debossed with "TL 175" on one side and scored on the other side. Bottles of 100 tablets with Child Resistant Closure, NDC 59746-175-06 Bottles of 500 NDC 59746-175-09 Bottles of 1000 NDC 59746-175-10 50 mg - White, round tablets debossed with "C 783" on one side and scored on the other side. Bottles of 100 tablets with Child Resistant Closure, NDC 59746-783-01 Store at 20° to 25° C (68° to 77° F) [See USP Room Temperature]. Manufactured by: Jubilant Cadista Pharmaceuticals Inc. Salisbury, MD 21801, USA. Revised 09/2021
Abbreviated New Drug Application
PREDNISONE- PREDNISONE TABLET PREDNISONE - PREDNISONE TABLET JUBILANT CADISTA PHARMACEUTICALS INC. ---------- PREDNISONE TABLETS, USP RX ONLY DESCRIPTION Prednisone, USP is a glucocorticoid. Glucocorticoids are adrenocortical steroids, both naturally occurring and synthetic, which are readily absorbed from the gastrointestinal tract. Prednisone, USP is a white to practically white, odorless, crystalline powder. It is very slightly soluble in water; slightly soluble in alcohol, in chloroform, in dioxane, and in methanol. The chemical name for prednisone is pregna-1,4-diene-3,11,20-trione, 17,21-dihydroxy- and its molecular weight is 358.43 The structural formula is represented below: Prednisone Tablets, USP are available in 5 strengths: 2.5 mg, 5 mg, 10 mg, 20 mg, and 50 mg. In addition, each tablet contains the following inactive Ingredients: Lactose Monohydrate, Magnesium Stearate, Pregelatinized Starch, Sodium Lauryl Sulfate and Sodium Starch Glycolate. Also Prednisone Tablets USP, 20 mg contains FD & C yellow # 6, aluminum lake, HT 15-18%. ACTIONS Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt- retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their potent anti-inflammatory effects in disorders of many organ systems. Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body's immune responses to diverse stimuli. INDICATIONS Prednisone Tablets, USP are indicated in the following conditions: 1. ENDOCRINE DISORDERS Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. RHEUMATIC DISORDERS As adjunctive therapy for short-term administration (to tide th קרא את המסמך השלם